{"id":10345,"date":"2026-07-11T12:27:59","date_gmt":"2026-07-11T09:27:59","guid":{"rendered":"https:\/\/jordan-cardiac.org\/?p=10345"},"modified":"2026-07-11T12:27:59","modified_gmt":"2026-07-11T09:27:59","slug":"2026-acc-scientific-statement-doac-therapy","status":"publish","type":"post","link":"https:\/\/jordan-cardiac.org\/en\/2026-acc-scientific-statement-doac-therapy\/","title":{"rendered":"2026 ACC Scientific Statement: DOAC Therapy"},"content":{"rendered":"<p>2026 ACC Scientific Statement: DOAC Therapy<\/p>\n<p>Source: JACC \u2014 2026 ACC Scientific Statement. June 30, 2026.<\/p>\n<p>\u2022\u2060 \u2060The ACC released a new scientific statement to improve the appropriate use of DOACs.<br \/>\n\u2022\u2060 \u2060DOACs are preferred over warfarin in many clinical settings because they have fewer drug interactions, predictable dosing, and a lower risk of intracranial bleeding.<br \/>\n\u2022\u2060 \u2060The statement emphasizes using the correct dose, regular assessment of kidney and liver function, bleeding risk, drug interactions, and medication adherence.<br \/>\n\u2022\u2060 \u2060Bleeding risk scores should identify patients who need closer follow-up, not be used alone to withhold anticoagulation.<br \/>\n\u2022\u2060 \u2060Practical recommendations are provided for patients with AF, VTE, CKD, liver disease, obesity, cancer, valvular heart disease, and around surgical or catheter-based procedures.<br \/>\n\u2022\u2060 \u2060Factor XI\/XIa inhibitors are highlighted as promising future anticoagulants that may reduce bleeding while maintaining antithrombotic efficacy.<\/p>\n<p>&nbsp;<\/p>\n<p><a href=\"https:\/\/www.jacc.org\/doi\/10.1016\/j.jacc.2026.05.033\">https:\/\/www.jacc.org\/doi\/10.1016\/j.jacc.2026.05.033<\/a><\/p>\n","protected":false},"excerpt":{"rendered":"<p>2026 ACC Scientific Statement: DOAC Therapy Source: JACC \u2014 2026 ACC Scientific Statement. June 30, 2026. \u2022\u2060 \u2060The ACC released a new scientific statement to improve the appropriate use of DOACs. \u2022\u2060 \u2060DOACs are preferred over warfarin in many clinical settings because they have fewer drug interactions, predictable dosing, and a lower risk of intracranial [&hellip;]<\/p>\n","protected":false},"author":145,"featured_media":0,"comment_status":"closed","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[1],"tags":[],"class_list":["post-10345","post","type-post","status-publish","format-standard","hentry","category-uncategorized"],"_links":{"self":[{"href":"https:\/\/jordan-cardiac.org\/en\/wp-json\/wp\/v2\/posts\/10345","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/jordan-cardiac.org\/en\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/jordan-cardiac.org\/en\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/jordan-cardiac.org\/en\/wp-json\/wp\/v2\/users\/145"}],"replies":[{"embeddable":true,"href":"https:\/\/jordan-cardiac.org\/en\/wp-json\/wp\/v2\/comments?post=10345"}],"version-history":[{"count":1,"href":"https:\/\/jordan-cardiac.org\/en\/wp-json\/wp\/v2\/posts\/10345\/revisions"}],"predecessor-version":[{"id":10346,"href":"https:\/\/jordan-cardiac.org\/en\/wp-json\/wp\/v2\/posts\/10345\/revisions\/10346"}],"wp:attachment":[{"href":"https:\/\/jordan-cardiac.org\/en\/wp-json\/wp\/v2\/media?parent=10345"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/jordan-cardiac.org\/en\/wp-json\/wp\/v2\/categories?post=10345"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/jordan-cardiac.org\/en\/wp-json\/wp\/v2\/tags?post=10345"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}